Henry Ford Health
Detroit, Michigan, United States
Lisa Rogers DO. I am Senior Staff at Henry Ford Health and Medical Director of the brain metastasis program. Throughout my career, I have directed or participated in many brain tumor treatment trials, including those of National Cancer Institute cooperative groups such as NRG Oncology, American Brain Tumor Consortium, and Alliance. In 2017 I served as the Case Comprehensive Cancer Center institutional representative for the NCCN Central Nervous System Cancers Guidelines. I am past president of the American Academy of Neurology Neuro-oncology Section and have organized and participated in educational symposia for the American Academy of Neurology and the Society for Neuro-oncology. A major focus of my clinical practice and research is the neurological complications of cance, including brain metastasis. I have designed and participated in multisite brain metastasis treatment protocols. I have decades of experience in the evaluation and management of cancer patients with non-metastatic neurologic complications, most commonly cognitive impairment and chemotherapy-induced neuropathy. I am a consultant for a laboratory model of brain metastasis utilizing propofol as a therapeutic agent and this is currently being translated into a clinical trial. I have investigated and published the sensitivity and specificity of advanced imaging, including MRI textural analysis, to distinguish recurrent brain metastasis from recurrent tumor.
Another clinical focus is in therapeutics and imaging of glioblastoma. I recently designed and conducted a multisite trial of the ketogenic diet in combination with anti-angiogenic therapy for recurrent glioblastoma. In 2023 I served as cochair of a glioblastoma metabolism workshop at the Society for Brain Mapping and Therapeutics conference. I recently served as Co-Principal Investigator of the ABTC trial of methoxyamine in combination with temolozomide for recurrent glioblastoma (manuscript under second review). I participate in the ReSPOND radiomics consortium.
